Income Statement
SILENCE THERAPEUTICS PLC
SLN
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Revenue
|
0.60 | 43.26 |
|
Cost of Revenue
|
0.22 | 11.81 |
|
Gross Profit
|
0.34 | 31.45 |
|
Operating Expenses
|
90.10 | 94.77 |
|
Research & Development
|
67.75 | 67.88 |
|
Selling, General & Administrative
|
22.34 | 26.88 |
|
Other Operating Expenses
|
- | - |
|
Operating Income
|
-89.75 | -63.32 |
|
Non-Operating Income
|
-1.15 | -18.86 |
|
Interest Income
|
- | - |
|
Interest Expense
|
- | - |
|
Other Non-Op Income / Expense
|
- | - |
|
Income Before Tax
|
-88.60 | -44.46 |
|
Income Tax Expense
|
0.01 | 0.85 |
|
Non-Controlling Interest
|
- | - |
|
Net Income
|
-88.61 | -45.31 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY |
|---|---|---|
|
Depreciation & Amortization
|
- | - |
|
EBITDA
|
-89.75 | -63.32 |
|
Earnings Per Share (Basic)
|
-0.63 | -0.33 |
|
Diluted EPS
|
-0.63 | -0.33 |
|
Weighted Average Shares
|
141.69 | 138.75 |
|
Diluted Weighted Avg Shares
|
141.69 | 138.75 |
|
Comprehensive Income
|
-79.81 | -46.36 |